No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.1x · 10Y median 0.9x · 2nd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2025-08-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2026-08-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2026-08-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2025-05-08.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2025-08-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2026-08-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:41:18.530Z. Latest historical point 2026-08-17. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for DocGo Inc. (DCGO) stock was $0.37 as of Oct 5, 2026, 4:00 PM EDT, down 1.22% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -71.1% · 3-year avg -60.2%/yr · 5-year avg -48.4%/yr
DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom.
Medical - Care Facilities · New York City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.11
Revenue Est.
$77.25M
Last Quarter Results
EPS
$-0.26
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DCGO | $36.05M | $0.36 | -1.22% | -71.09% | -48.40% | N/A | N/A |
| 2ARAY | $35.89M | $0.30 | +7.37% | -82.00% | -39.94% | -25.77% | vs DCGO |
| 3BEAT | $36.31M | $0.65 | +50.53% | -66.28% | N/A | N/A | vs DCGO |
| 4ELUT | $36.32M | $0.82 | +5.51% | -6.61% | -33.96% | N/A | vs DCGO |
| 5BCTX | $36.37M | $4.18 | +3.47% | -67.87% | -67.32% | -52.81% | vs DCGO |
| 6ELTX | $36.61M | $1.92 | +0.00% | -82.46% | N/A | N/A | vs DCGO |
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$73.42M
vs Estimate
$75.35M
Consensus Rating
Based on 4 analysts
Average Price Target
$1.88
+413.8% upside
Low
$1.00
Current
$0.36
High
$3.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.11 | $-0.09 | $-0.08 | 2 |
| Quarter ending Dec 2026 | $-0.58 | $-0.07 | $0.44 | 2 |
| Quarter ending Mar 2027 | $-0.09 | $-0.09 | $-0.08 | 1 |
| Quarter ending Jun 2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.58 | $-0.51 | $-0.42 | 2 |
| FY 2027 | $-0.94 | $-0.27 | $0.41 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $76.27M | $77.25M | $78.21M | 3 |
| Quarter ending Dec 2026 | $79.31M | $80.28M | $81.25M | 3 |
| Quarter ending Mar 2027 | $78.87M | $79.86M | $81.30M | 1 |
| Quarter ending Jun 2027 | $76.90M | $77.86M | $79.26M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $306.48M | $306.50M | $306.53M | 4 |
| FY 2027 | $324.80M | $325.77M | $326.73M | 4 |
